COVID-19 (SARS-CoV-2 - Coronaviruses)

Overview

Plain-Language Overview

COVID-19 is an infectious disease caused by the SARS-CoV-2 virus, primarily affecting the respiratory system. It spreads mainly through respiratory droplets when an infected person coughs, sneezes, or talks. The illness can range from mild symptoms like fever, cough, and fatigue to severe respiratory distress requiring hospitalization. In some cases, it can lead to complications such as pneumonia or affect other organs. The disease has caused a global pandemic due to its high transmissibility and impact on public health.

Clinical Definition

COVID-19 is a viral respiratory illness caused by the SARS-CoV-2, a novel coronavirus that infects host cells via the ACE2 receptor. The infection primarily targets the lower respiratory tract, leading to inflammation and damage to alveolar cells, which can cause viral pneumonia and acute respiratory distress syndrome (ARDS). The disease manifests with a spectrum of clinical severity, from asymptomatic to critical illness with multi-organ failure. Transmission occurs through respiratory droplets and aerosols, with a high basic reproduction number (R0). The immune response includes both innate and adaptive components, and dysregulated inflammation can contribute to severe disease. COVID-19 has significant clinical importance due to its rapid spread, potential for severe respiratory compromise, and systemic complications.

Inciting Event

Exposure to respiratory droplets containing SARS-CoV-2 from infected individuals.
Close contact with symptomatic or asymptomatic carriers in enclosed spaces.
Inhalation of aerosolized virus particles during medical procedures or crowded indoor settings.
Fomite transmission via contaminated surfaces followed by mucous membrane contact.

Latency Period

The incubation period ranges from 2 to 14 days, with a median of about 5 days.
Symptoms typically develop within 4 to 5 days after exposure to the virus.
Asymptomatic infection can occur despite viral replication during this period.

Diagnostic Delay

Initial symptoms often mimic common viral illnesses leading to misattribution as influenza or common cold.
Limited access to RT-PCR testing early in the pandemic caused delayed diagnosis.
Asymptomatic or mild cases may not seek medical attention, delaying detection.
Overlap with other respiratory infections complicates clinical diagnosis without testing.

Patient Population

Adults over 60 years have the highest risk of severe disease and death.
Males tend to have more severe disease compared to females.
Residents of congregate settings such as nursing homes are disproportionately affected.
Healthcare workers have increased exposure risk but variable disease severity.
Individuals with multiple comorbidities are more commonly hospitalized.

Risk Factors

Advanced age is the strongest risk factor for severe COVID-19 and mortality.
Underlying cardiovascular disease increases risk of complications and death.
Obesity is associated with increased severity due to chronic inflammation and impaired respiratory mechanics.
Diabetes mellitus predisposes to worse outcomes through immune dysfunction.
Immunosuppression from medications or conditions increases susceptibility to severe infection.

Clinical Presentation

Signs & Symptoms

Fever, dry cough, and fatigue are the most common presenting symptoms.
Dyspnea develops in moderate to severe cases indicating lower respiratory tract involvement.
Anosmia and ageusia are distinctive early neurological symptoms.
Myalgias and headache frequently accompany systemic viral illness.
Gastrointestinal symptoms such as diarrhea and nausea occur in a subset of patients.

History of Present Illness

Initial symptoms commonly include fever, dry cough, and fatigue progressing over days.
Dyspnea and hypoxia develop in moderate to severe cases typically after 5-7 days.
Some patients report anosmia and ageusia as early or isolated symptoms.
Gastrointestinal symptoms like diarrhea and nausea may precede respiratory complaints.
Severe cases progress to ARDS, multi-organ failure, and shock.

Past Medical History

Chronic lung diseases such as COPD or asthma increase risk of severe COVID-19.
Cardiovascular diseases including hypertension and heart failure worsen prognosis.
Diabetes mellitus is associated with impaired immune response and complications.
History of immunosuppressive therapy or conditions increases susceptibility.
Previous vaccination status against COVID-19 modifies disease severity and outcomes.

Family History

No specific heritable syndromes are linked to COVID-19 susceptibility or severity.
Family clusters are common due to shared exposure and transmission rather than genetics.
Rare genetic variants affecting type I interferon pathways may predispose to severe disease.
No consistent familial pattern of severe COVID-19 has been established.

Physical Exam Findings

Fever and tachypnea are common vital sign abnormalities in COVID-19 patients.
Hypoxia with decreased oxygen saturation is frequently observed in moderate to severe cases.
Crackles or rales may be heard on lung auscultation indicating pulmonary involvement.
Tachycardia can occur secondary to fever or hypoxia.
Conjunctival injection or mild pharyngeal erythema may be present in some cases.

Physical Exam Maneuvers

Pulse oximetry is essential for assessing oxygenation status in suspected COVID-19 patients.
6-minute walk test can help evaluate exertional desaturation and functional capacity.
Lung auscultation is critical to detect abnormal breath sounds such as crackles.
Respiratory rate measurement is a simple bedside assessment for respiratory distress.
Chest expansion assessment may reveal decreased movement in severe lung involvement.

Common Comorbidities

Hypertension is frequently associated with severe COVID-19 outcomes.
Diabetes mellitus increases risk of severe disease and complications.
Obesity is a significant risk factor for hospitalization and respiratory failure.
Chronic lung diseases such as COPD predispose to worse respiratory outcomes.
Cardiovascular disease is linked to increased mortality in COVID-19 patients.

Diagnostic Workup

Diagnostic Criteria

Diagnosis of COVID-19 is established primarily by detecting viral RNA using reverse transcription polymerase chain reaction (RT-PCR) from nasopharyngeal or oropharyngeal swabs. Positive RT-PCR confirms active infection. Antigen tests provide faster but less sensitive detection of viral proteins. Clinical presentation with typical symptoms such as fever, cough, and dyspnea supports diagnosis, especially during outbreaks. Imaging such as chest CT may show characteristic ground-glass opacities but is not diagnostic without laboratory confirmation.

Pathophysiology

Key Mechanisms

Viral entry via binding of the SARS-CoV-2 spike protein to the ACE2 receptor on host cells.
Dysregulated immune response causing a cytokine storm with elevated proinflammatory cytokines like IL-6 and TNF-alpha.
Endothelial injury leading to microvascular thrombosis and coagulopathy.
Diffuse alveolar damage resulting in impaired gas exchange and acute respiratory distress syndrome (ARDS).
Viral replication in respiratory epithelial cells causing direct cytopathic effects.

Involvement	Details
Organs	Lungs are the main organs affected, with viral pneumonia leading to hypoxemia and acute respiratory distress syndrome
	Heart may be involved via myocarditis, arrhythmias, or ischemic injury secondary to systemic inflammation
	Kidneys can suffer acute injury due to direct viral effects, hypoxia, and microthrombi
	Brain involvement can cause neurological symptoms from direct viral invasion or secondary inflammation
Tissues	Pulmonary alveolar tissue is the primary site of viral infection and inflammatory damage causing respiratory symptoms
Tissues	Vascular endothelium is involved in microvascular injury and thrombosis contributing to multi-organ dysfunction
Cells	Type II pneumocytes are the primary target cells for SARS-CoV-2 entry and replication in the lungs
	Alveolar macrophages contribute to the inflammatory response and cytokine release in COVID-19 pneumonia
	T lymphocytes mediate adaptive immune response but may undergo depletion in severe disease
	Endothelial cells are involved in vascular inflammation and thrombosis associated with COVID-19
Chemical Mediators	Interleukin-6 (IL-6) is a key cytokine driving the cytokine storm and systemic inflammation in severe COVID-19
	Tumor necrosis factor-alpha (TNF-α) promotes inflammation and tissue damage in infected lungs
	C-reactive protein (CRP) is an acute phase reactant elevated in systemic inflammation and used as a disease severity marker
	D-dimer is elevated due to hypercoagulability and is associated with thrombotic complications

Treatments

Pharmacological Treatments

Remdesivir
- Mechanism:
  - Inhibits viral RNA-dependent RNA polymerase, blocking SARS-CoV-2 replication
- Side effects:
  - Elevated liver enzymes
  - Nausea
  - Hypersensitivity reactions
- Clinical role:
  - First-line
Dexamethasone
- Mechanism:
  - Suppresses systemic inflammation by modulating immune response and cytokine production
- Side effects:
  - Hyperglycemia
  - Immunosuppression
  - Psychiatric disturbances
- Clinical role:
  - Adjunctive
Tocilizumab
- Mechanism:
  - Blocks IL-6 receptor to reduce cytokine storm and severe inflammatory response
- Side effects:
  - Increased infection risk
  - Hepatotoxicity
  - Neutropenia
- Clinical role:
  - Second-line
Baricitinib
- Mechanism:
  - Janus kinase inhibitor that reduces cytokine signaling and inflammation
- Side effects:
  - Thrombosis
  - Infections
  - Elevated liver enzymes
- Clinical role:
  - Second-line
Monoclonal antibodies (e.g., sotrovimab)
- Mechanism:
  - Neutralizes SARS-CoV-2 by binding spike protein to prevent viral entry
- Side effects:
  - Infusion reactions
  - Hypersensitivity
  - Anaphylaxis
- Clinical role:
  - First-line for early mild-to-moderate disease

Non-pharmacological Treatments

Supplemental oxygen therapy to maintain adequate oxygen saturation in hypoxemic patients
Mechanical ventilation for patients with respiratory failure due to severe COVID-19 pneumonia
Prone positioning to improve ventilation-perfusion matching and oxygenation in ARDS
Use of high-flow nasal cannula to support oxygenation while avoiding intubation
Strict infection control measures including isolation and use of personal protective equipment

Prevention

Pharmacological Prevention

mRNA vaccines (e.g., Pfizer-BioNTech, Moderna) provide effective prevention against COVID-19.
Viral vector vaccines (e.g., Johnson & Johnson) offer alternative immunization options.
Monoclonal antibody prophylaxis is used in high-risk individuals with contraindications to vaccination.
Antiviral agents are not currently recommended for primary prophylaxis but are used in treatment.
Booster doses enhance and prolong vaccine-induced immunity against emerging variants.

Non-pharmacological Prevention

Mask wearing reduces transmission by blocking respiratory droplets.
Physical distancing limits close contact and viral spread.
Hand hygiene with soap or alcohol-based sanitizers decreases fomite transmission.
Ventilation improvements in indoor spaces reduce airborne viral concentration.
Quarantine and isolation of exposed or infected individuals prevent community outbreaks.

Outcome & Complications

Complications

Acute respiratory distress syndrome (ARDS) is a life-threatening pulmonary complication.
Thromboembolic events including pulmonary embolism and stroke are common due to hypercoagulability.
Secondary bacterial pneumonia can complicate severe COVID-19 cases.
Myocarditis and cardiac arrhythmias may occur due to direct viral or inflammatory injury.
Multisystem inflammatory syndrome can develop, especially in children and young adults.

Short-term Sequelae	Long-term Sequelae
Prolonged hypoxia requiring supplemental oxygen or mechanical ventilation. Persistent fatigue and cough lasting weeks after acute infection. Post-viral anosmia or ageusia may persist beyond initial illness. Acute kidney injury secondary to systemic illness or nephrotoxic treatments. Neurocognitive symptoms such as confusion or delirium during acute illness.	Post-acute COVID-19 syndrome (long COVID) characterized by fatigue, dyspnea, and cognitive impairment. Pulmonary fibrosis may develop after severe lung injury. Chronic thromboembolic pulmonary hypertension can result from unresolved emboli. Persistent neuropsychiatric symptoms including anxiety, depression, and brain fog. Cardiac dysfunction such as reduced ejection fraction or arrhythmias may persist.

Short-term Sequelae

Long-term Sequelae

Prolonged hypoxia requiring supplemental oxygen or mechanical ventilation.
Persistent fatigue and cough lasting weeks after acute infection.
Post-viral anosmia or ageusia may persist beyond initial illness.
Acute kidney injury secondary to systemic illness or nephrotoxic treatments.
Neurocognitive symptoms such as confusion or delirium during acute illness.

Post-acute COVID-19 syndrome (long COVID) characterized by fatigue, dyspnea, and cognitive impairment.
Pulmonary fibrosis may develop after severe lung injury.
Chronic thromboembolic pulmonary hypertension can result from unresolved emboli.
Persistent neuropsychiatric symptoms including anxiety, depression, and brain fog.
Cardiac dysfunction such as reduced ejection fraction or arrhythmias may persist.

Differential Diagnoses

COVID-19 (SARS-CoV-2 - Coronaviruses) versus Influenza

COVID-19 (SARS-CoV-2 - Coronaviruses)	Influenza
Widespread pandemic potential with variable seasonality and global spread	Seasonal outbreaks with rapid person-to-person spread, often in winter
Positive SARS-CoV-2 PCR or antigen test	Positive rapid influenza antigen or PCR test
Variable symptom onset with possible prolonged respiratory symptoms and post-viral complications	Abrupt onset of symptoms with high fever, myalgia, and cough resolving in 1-2 weeks

COVID-19 (SARS-CoV-2 - Coronaviruses) versus Respiratory Syncytial Virus (RSV) Infection

COVID-19 (SARS-CoV-2 - Coronaviruses)	Respiratory Syncytial Virus (RSV) Infection
Affects all age groups, with severe disease more common in elderly and immunocompromised	Primarily affects infants and young children
Single-stranded positive-sense RNA virus of the Coronaviridae family	Single-stranded negative-sense RNA virus of the Paramyxoviridae family
Predominantly pneumonia and systemic symptoms with variable respiratory involvement	Bronchiolitis with wheezing and respiratory distress in infants

COVID-19 (SARS-CoV-2 - Coronaviruses) versus Bacterial Pneumonia

COVID-19 (SARS-CoV-2 - Coronaviruses)	Bacterial Pneumonia
Normal or mildly elevated procalcitonin with lymphopenia	Elevated procalcitonin and neutrophilic leukocytosis
Bilateral ground-glass opacities or patchy infiltrates on chest CT	Lobar consolidation on chest X-ray
Requires antiviral therapy and supportive care; antibiotics ineffective unless secondary bacterial infection	Rapid improvement with appropriate antibiotics

COVID-19 (SARS-CoV-2 - Coronaviruses) versus Other Coronavirus Infections (e.g., SARS, MERS)

COVID-19 (SARS-CoV-2 - Coronaviruses)	Other Coronavirus Infections (e.g., SARS, MERS)
Global community spread with widespread human-to-human transmission	Exposure linked to specific geographic regions or animal reservoirs
Positive PCR specific for SARS-CoV-2	Positive PCR specific for SARS-CoV or MERS-CoV
Variable severity with lower overall mortality but potential for severe disease	Higher case fatality rate with more severe respiratory failure

COVID-19 (SARS-CoV-2 - Coronaviruses) versus Community-Acquired Pneumonia due to Atypical Bacteria (e.g., Mycoplasma pneumoniae)

COVID-19 (SARS-CoV-2 - Coronaviruses)	Community-Acquired Pneumonia due to Atypical Bacteria (e.g., Mycoplasma pneumoniae)
Lymphopenia and elevated inflammatory markers without cold agglutinins	Normal or mildly elevated white blood cell count with cold agglutinins
Variable onset with fever, cough, and systemic symptoms	Gradual onset of dry cough and low-grade fever
Requires antiviral agents and supportive care	Improvement with macrolides or tetracyclines